News headlines about Eleven Biotherapeutics (NASDAQ:EBIO) have trended positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8066359295065 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s analysis:

Shares of Eleven Biotherapeutics (NASDAQ EBIO) traded down $0.01 during mid-day trading on Tuesday, reaching $0.87. 564,500 shares of the company’s stock traded hands, compared to its average volume of 787,320. The stock has a market cap of $27.69, a PE ratio of -0.82 and a beta of 3.04. Eleven Biotherapeutics has a 1-year low of $0.62 and a 1-year high of $2.54.

TRADEMARK VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Impact Eleven Biotherapeutics (EBIO) Stock Price” was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/positive-media-coverage-somewhat-unlikely-to-impact-eleven-biotherapeutics-ebio-stock-price/1800135.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Insider Buying and Selling by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.